According to a recent LinkedIn post from Colossal Biosciences, the company used a Mother’s Day theme to illustrate the complexity of its de-extinction work by asking its founders’ mothers to explain what the firm does. The post characterizes Colossal as the “world’s only de-extinction company” and notes that its activities span genome engineering, embryology, cryopreservation, assisted reproduction, computational biology, and animal husbandry.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Colossal is positioning itself as a highly specialized player at the intersection of multiple advanced life-sciences disciplines, emphasizing both technological breadth and novelty. For investors, this messaging may underscore the company’s ambition to build a defensible niche in de-extinction and conservation-related biotechnology, while also hinting at the communication and education challenges inherent in such an emerging, unconventional business model.
By aligning its mission with themes of “giving life” and “protecting it,” the post appears to link de-extinction to broader conservation and biosecurity narratives rather than purely speculative science. This framing could be relevant for investors assessing long-term monetization pathways, including potential applications in biodiversity preservation, reproductive technologies, and genomic tools that might have adjacent commercial uses beyond de-extinction itself.